Full Breakdown
COVID-19 Vaccination Linked to Reduced Preeclampsia Risk in Pregnant Women
2/20/2026, 10:55:26 PM
Overview of the Study Findings
A large international study published on February 18, 2026, in *eClinicalMedicine* indicates that COVID-19 vaccination, particularly with a booster dose, significantly reduces the risk of preeclampsia in pregnant women. Conducted by the INTERCOVID Consortium, the study analyzed data from 6,527 pregnant women across 18 countries between 2020 and 2022. It found that COVID-19 infection during pregnancy increased the risk of preeclampsia by 45%, which escalated to 78% among unvaccinated women. In contrast, vaccinated women experienced a 33% reduction in preeclampsia odds, with even greater protection (42%) noted among those with pre-existing health conditions such as diabetes or hypertension.
Implications for Maternal Health
The findings suggest that COVID-19 vaccination may influence biological pathways involved in preeclampsia development, offering broader immunological and vascular benefits beyond merely preventing COVID-19 infection. Vaccinated women also reported lower rates of preterm births and severe complications during delivery. The study emphasizes the importance of integrating COVID-19 vaccination into standard prenatal care, particularly for high-risk populations.
Official Statements & Responses
Dr. Jagjit Teji, a co-author of the study and neonatologist at Lurie Children’s Hospital, stated, “Our results support the importance of strengthening COVID vaccination programs during pregnancy, emphasizing boosters and ensuring that pregnant people across the world have equitable access to the vaccine.” Professor José Villar, the principal investigator of the INTERCOVID consortium, noted, “We now have evidence that maternal vaccination may influence pathways involved in preeclampsia development, suggesting a broader immunological or vascular benefit of vaccination.”
Criticism & Opposition
While the study presents compelling evidence, some experts caution against over-reliance on vaccination as a sole preventive measure for preeclampsia, emphasizing the need for comprehensive prenatal care that includes monitoring and managing other risk factors.
Conflicting Reports & Gaps
There are no significant conflicting reports regarding the study's findings; however, the exact mechanisms by which vaccination influences preeclampsia pathways remain an area for further research. The study did not explore long-term outcomes for mothers and infants post-vaccination.
Verbatim Quotes
- “Our results support the importance of strengthening COVID vaccination programs during pregnancy, emphasizing boosters and ensuring that pregnant people across the world have equitable access to the vaccine,” — Dr. Jagjit Teji, Neonatologist, Lurie Children’s Hospital
- “We now have evidence that maternal vaccination may influence pathways involved in preeclampsia development, suggesting a broader immunological or vascular benefit of vaccination.” — Professor José Villar, Principal Investigator, INTERCOVID Consortium
What's Next
The findings from this study may prompt health authorities to prioritize COVID-19 vaccination campaigns for pregnant women, particularly in low- and middle-income countries, to mitigate disparities in maternal and neonatal health outcomes. Further research is anticipated to explore the long-term effects of vaccination on both mothers and infants.
